Study Finds Adaptive Biotechnologies’ Next-Generation Sequencing-Based Technology Can Detect Hodgkin Lymphoma Disease Recurrence

Adaptive Biotechnologies’ next-generation genetic diagnostic technology has demonstrated the potential to detect trace amounts of classical Hodgkin’s lymphoma (CHL) that remains in the body after treatment.

Researchers at The University of Texas MD Anderson Cancer Center conducted a study showing that Adaptive Biotechnologies’ next-generation sequencing-based approach to identification and quantification of populations of B cells can detect tumor-specific DNA sequences in the blood of people with CHL. The results, published in the British Journal of Haematology, represents a first step toward developing a test that will allow physicians to better assess patients’ response to initial treatment and to detect disease recurrence by simple blood draw rather than radiographic imaging studies.

Roughly 20 to 30 percent of CHL patients suffer from treatment-resistant or recurrent disease. However, predicting which patients will do so is challenging since minimal residual disease (MRD) is difficult to detect using an assay-based approach. Since they residual cancer cells are present at low levels, they are undetectable by traditional microscopic exams or lymph node biopsies.

“Accurate determination of disease status after completion of treatment may provide new opportunities for formulating surveillance and/or management strategies,” said Anas Younes, MD, who is now the Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, and senior author of the study.

Adaptive Biotechnologies’ clonoSEQ process enables physicians to utilize sequencing-based MRD detection to support clinical decision making for patients with blood cancers. The company says clonSEQ can detect cancer cells at levels as low as one per one million white blood cells by detecting previously identified DNA sequences of malignant Hodgkin Reed-Sternberg (HRS) cells.

Researchers from MD Anderson used clonoSEQ to test 17 CHL patients for lymphoma-specific sequences. The diagnostic test is used in a two-step approach. In the first step, the clonoSEQ ID test, cancer cell DNA sequences are identified in a diagnostic sample. In the second step, the clonoSEQ MRD test, follow-up samples are screened for the previously identified sequences in order to detect residual disease. The test results are generated in seven days, using Adaptive’s CLIA-certified, CAP-accredited laboratory. The results are then provided to the physician in a simple, actionable report that shows a patient’s MRD status and level, as well as MRD trends over time through a secure online portal.

“The immunosequencing technology that was used in this study allows for ultrasensitive detection of lymphoma-specific DNA signatures. This technology is at the heart of our clonoSEQ process, which has so far been validated for the detection and quantification of minimal residual disease in myeloma and several types of leukemia and non-Hodgkin’s lymphoma,” said Tom Willis, PhD, Senior Vice President and General Manager, Diagnostics Products, Adaptive Biotechnologies. “’This study shows that our technology also has the potential to impact the clinical care of patients with Hodgkin’s lymphoma.”

Source: Adaptive Biotechnologies

Last updated: 4/29/15; 3:35pm EST



Check Also

FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: …

Leave a Reply

Your email address will not be published. Required fields are marked *